EXACT Sciences (NASDAQ:EXAS) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

A number of other equities analysts have also commented on the company. Bank of America increased their price target on EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, November 29th. Leerink Swann reaffirmed an “outperform” rating and issued a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a research note on Monday, November 13th. Robert W. Baird lowered EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective for the company. in a research note on Monday, November 13th. Zacks Investment Research lowered EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, BTIG Research lowered EXACT Sciences from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 1st. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $50.58.

Shares of EXACT Sciences (NASDAQ EXAS) traded down $0.61 during trading on Wednesday, reaching $53.83. The company had a trading volume of 1,532,605 shares, compared to its average volume of 1,238,164. EXACT Sciences has a 52 week low of $13.05 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. During the same period in the prior year, the company earned ($0.36) earnings per share. The firm’s revenue was up 158.4% on a year-over-year basis. research analysts predict that EXACT Sciences will post -1.12 earnings per share for the current year.

In other news, SVP D Scott Coward sold 29,115 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the sale, the senior vice president now directly owns 64,991 shares in the company, valued at $3,064,975.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin T. Conroy sold 137,805 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total value of $8,149,787.70. Following the completion of the sale, the chief executive officer now owns 967,867 shares in the company, valued at $57,239,654.38. The disclosure for this sale can be found here. Insiders sold a total of 595,396 shares of company stock valued at $32,953,769 over the last ninety days. Corporate insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Advisor Group Inc. increased its holdings in EXACT Sciences by 0.8% during the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock worth $270,000 after purchasing an additional 65 shares during the period. Ameritas Investment Partners Inc. increased its holdings in EXACT Sciences by 5.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after purchasing an additional 511 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in EXACT Sciences by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares during the period. Lincoln National Corp increased its holdings in EXACT Sciences by 7.8% during the 2nd quarter. Lincoln National Corp now owns 10,104 shares of the medical research company’s stock worth $357,000 after purchasing an additional 728 shares during the period. Finally, Amalgamated Bank increased its holdings in EXACT Sciences by 6.0% during the 3rd quarter. Amalgamated Bank now owns 14,964 shares of the medical research company’s stock worth $705,000 after purchasing an additional 845 shares during the period. Hedge funds and other institutional investors own 82.39% of the company’s stock.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/10/exact-sciences-exas-stock-rating-lowered-by-bidaskclub.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.